JP5183496B2 - 成長ホルモンのペプチド性分泌促進物質に類似した化合物及びそれを含有する製剤 - Google Patents

成長ホルモンのペプチド性分泌促進物質に類似した化合物及びそれを含有する製剤 Download PDF

Info

Publication number
JP5183496B2
JP5183496B2 JP2008556643A JP2008556643A JP5183496B2 JP 5183496 B2 JP5183496 B2 JP 5183496B2 JP 2008556643 A JP2008556643 A JP 2008556643A JP 2008556643 A JP2008556643 A JP 2008556643A JP 5183496 B2 JP5183496 B2 JP 5183496B2
Authority
JP
Japan
Prior art keywords
ghrelin
ghs
compound
growth hormone
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008556643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528303A (ja
JP2009528303A5 (cg-RX-API-DMAC7.html
Inventor
フェルナンデス、ローランド、エドゥアルド ロドリゲス
ラ ヌエス ベウレンス、アニア デ
ガルシア、マリオ、パブロ エストラーダ
ロドリゲス、レベッカ マルティネス
サンティアゴ、グレイ チネア
アコスタ、オスバルド レイエス
マッソ、ジュリオ、ラウル フェルナンデス
デル バルコ エレーラ、ダイアナ ガルシア
アコスタ、ホルヘ、アマドール ベルランガ
ラサ、アレクシス ムサッチオ
Original Assignee
セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40130780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5183496(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア filed Critical セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア
Publication of JP2009528303A publication Critical patent/JP2009528303A/ja
Publication of JP2009528303A5 publication Critical patent/JP2009528303A5/ja
Application granted granted Critical
Publication of JP5183496B2 publication Critical patent/JP5183496B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
JP2008556643A 2006-02-28 2007-02-28 成長ホルモンのペプチド性分泌促進物質に類似した化合物及びそれを含有する製剤 Expired - Fee Related JP5183496B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20060050A CU23558A1 (es) 2006-02-28 2006-02-28 Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU2006-0050 2006-02-28
PCT/CU2007/000007 WO2007098716A1 (es) 2006-02-28 2007-02-28 Compuestos analogos a los secretagogos peptidicos de la hormona de crecimiento y preparaciones que los contienen

Publications (3)

Publication Number Publication Date
JP2009528303A JP2009528303A (ja) 2009-08-06
JP2009528303A5 JP2009528303A5 (cg-RX-API-DMAC7.html) 2010-04-15
JP5183496B2 true JP5183496B2 (ja) 2013-04-17

Family

ID=40130780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008556643A Expired - Fee Related JP5183496B2 (ja) 2006-02-28 2007-02-28 成長ホルモンのペプチド性分泌促進物質に類似した化合物及びそれを含有する製剤

Country Status (18)

Country Link
US (1) US8367620B2 (cg-RX-API-DMAC7.html)
EP (1) EP1997827B1 (cg-RX-API-DMAC7.html)
JP (1) JP5183496B2 (cg-RX-API-DMAC7.html)
KR (1) KR101409277B1 (cg-RX-API-DMAC7.html)
CN (1) CN101432294B (cg-RX-API-DMAC7.html)
AR (1) AR059646A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007219569B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708366A2 (cg-RX-API-DMAC7.html)
CA (1) CA2637593C (cg-RX-API-DMAC7.html)
CL (2) CL2007000528A1 (cg-RX-API-DMAC7.html)
CU (1) CU23558A1 (cg-RX-API-DMAC7.html)
ES (1) ES2441441T3 (cg-RX-API-DMAC7.html)
MX (1) MX2008011142A (cg-RX-API-DMAC7.html)
MY (1) MY184130A (cg-RX-API-DMAC7.html)
NO (1) NO20084118L (cg-RX-API-DMAC7.html)
RU (1) RU2416618C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007098716A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807162B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4831551B2 (ja) * 2008-11-06 2011-12-07 国立大学法人名古屋大学 非虚血性心筋障害に対する医薬
CU24473B1 (es) * 2016-11-01 2020-02-04 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal
RU2734835C1 (ru) * 2020-02-11 2020-10-23 Федеральное государственное бюджетное учреждение науки Лимнологический институт Сибирского отделение Российской академии наук (ЛИН СО РАН) Способ повышения жизнестойкости эмбрионов рыб в аквакультуре

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DK0554381T3 (da) 1990-10-25 1996-04-09 Genentech Inc Anvendelse af beskyttende midler mod reaktive oxygenforbindelser
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
AU8083694A (en) 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9408019A (pt) 1993-11-09 1997-08-26 Merck & Co Inc Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5854211A (en) 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2179597A1 (en) 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
WO1996002530A1 (en) 1994-07-20 1996-02-01 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022996A1 (en) 1995-01-25 1996-08-01 Nippon Chemiphar Co., Ltd. Dihydrophenazine derivatives
MY113488A (en) 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534696A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
AU5486396A (en) 1995-04-19 1996-11-07 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
JP3133073B2 (ja) 1995-05-29 2001-02-05 ファイザー・インコーポレーテッド 成長ホルモンの放出を促進するジペプチド類
HUP9802821A3 (en) 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997007117A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
US5723616A (en) 1995-10-27 1998-03-03 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
JPH11513989A (ja) 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
BR9610887A (pt) 1995-10-27 1999-07-13 Merck & Co Inc Processo para a preparação de um composto
ES2229289T3 (es) 1995-12-13 2005-04-16 MERCK & CO., INC. Familia de receptores de secretagogo de la hormona del crecimiento.
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
AU715856B2 (en) 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
AU2382097A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1997040023A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU711884B2 (en) 1996-05-07 1999-10-21 Merck & Co., Inc. Enhancement of sleep with a growth hormone secretagogue
WO1997041878A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
AU2764797A (en) 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
JP2000512274A (ja) 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ 骨粗しょう症の周期的(整合性)治療における成長ホルモン成分及び骨抗吸収剤
EP1184370B1 (en) 1996-07-22 2005-09-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998018815A1 (en) 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
SE9703929D0 (sv) 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
JP2000514838A (ja) 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
US5861149A (en) 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
AU758160B2 (en) 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
IL137007A0 (en) 1998-01-16 2001-06-14 Novo Nordisk As Compounds with growth hormone releasing properties
WO1999039730A1 (en) 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Oral preparations containing peptides promoting the secretion of growth hormone
KR20010041533A (ko) 1998-03-03 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 (2e)-5-아미노-5-메틸헥스-2-엔오산n-메틸-n-((1r)-1-(n-메틸-n-((1r)-1-(메틸카르바모일)-2-페닐에틸)카르바모일)-2-(2-나프틸)에틸)아미드의신규한 염 형태
CZ301276B6 (cs) 1998-05-11 2009-12-30 Novo Nordisk A/S Piperidinový derivát vykazující schopnost uvolnování rustového hormonu
WO1999064456A1 (en) 1998-06-09 1999-12-16 Novo Nordisk A/S A method for preparing a compound with growth hormone releasing properties
AP9901582A0 (en) 1998-06-16 1999-06-30 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
AU3342099A (en) 1998-06-16 2000-01-05 Pfizer Products Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CN1304424C (zh) 1998-06-30 2007-03-14 诺沃挪第克公司 具有生长激素释放特性的化合物
CN1161333C (zh) 1998-08-20 2004-08-11 住友制药株式会社 作为生长激素释放剂的2-羟基吲哚衍生物
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
ATE304373T1 (de) * 1999-12-28 2005-09-15 Kaken Pharma Co Ltd Nervenschutzmittel
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
ATE302181T1 (de) 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
AU2001274601A1 (en) 2000-06-23 2002-01-02 Kaken Pharmaceutical Co., Ltd. Preventives or remedies for heart failure
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005039625A1 (en) 2003-10-28 2005-05-06 Rheoscience A/S Growth hormone secretagogue receptor agonists
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005048916A2 (en) 2003-11-20 2005-06-02 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders

Also Published As

Publication number Publication date
MX2008011142A (es) 2008-09-08
CN101432294B (zh) 2013-09-11
EP1997827A1 (en) 2008-12-03
WO2007098716A8 (es) 2008-12-18
CU23558A1 (es) 2010-07-20
ES2441441T3 (es) 2014-02-04
JP2009528303A (ja) 2009-08-06
RU2008138569A (ru) 2010-04-10
US8367620B2 (en) 2013-02-05
MY184130A (en) 2021-03-19
ZA200807162B (en) 2009-06-24
CN101432294A (zh) 2009-05-13
KR101409277B1 (ko) 2014-06-24
NO20084118L (no) 2008-09-29
US20100055118A1 (en) 2010-03-04
RU2416618C2 (ru) 2011-04-20
CA2637593C (en) 2015-04-14
CL2007000528A1 (es) 2008-01-18
CA2637593A1 (en) 2007-09-07
BRPI0708366A2 (pt) 2011-05-24
WO2007098716A1 (es) 2007-09-07
CL2016001648A1 (es) 2017-02-24
AU2007219569B2 (en) 2012-03-15
EP1997827B1 (en) 2013-10-09
AU2007219569A1 (en) 2007-09-07
AR059646A1 (es) 2008-04-16
KR20080110763A (ko) 2008-12-19

Similar Documents

Publication Publication Date Title
Gualillo et al. Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action
Baldanzi et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT
JP5134627B2 (ja) N末端で置換されたグレリン類似体
EP1729792B1 (en) Y4 selective receptor agonist for therapeutic interventions
Albarrán-Zeckler et al. The ghrelin receptors (GHS-R1a and GHS-R1b)
KR20180025966A (ko) 선택적 펩티드 이중 glp-1/글루카곤 수용체 효능제로서의 신규 엑센딘-4 유도체
EP2272524A2 (en) Y2 selective receptor agonists for therapeutic interventions
ZA200705031B (en) Y4 selective receptor agonists for therapeutic interventions
Vodnik et al. Ghrelin receptor ligands reaching clinical trials: from peptides to peptidomimetics; from agonists to antagonists
CA3093383A1 (en) Co-agonists of the glucagon and glp-1 receptors
CN119431514A (zh) 一种gcgr、gipr和glp-1r三重靶向激动作用的多肽衍生物
Eliakim et al. Exercise, training, and the GH-IGF-I axis
Kojima et al. Structure of mammalian and nonmammalian ghrelins
MXPA06010346A (es) Agonistas de receptor selectivo de y2/y4 para intervenciones terapeuticas.
WO2002060472A1 (fr) Remedes pour des etats d'hyponutrition
JP2026506334A (ja) Nmu受容体2アゴニスト
JP2009528303A (ja) 成長ホルモンのペプチド性分泌促進物質に類似した化合物及びそれを含有する製剤
Šaranac et al. The ghrelin system; beyond the role in energy homeostasis
Muccioli et al. Known and unknown growth hormone secretagogue receptors and their ligands
Kojima et al. Discovery of Ghrelin, an Endogenous Ligand for the Growth-Hormone Secret Agogue Receptor
KOJIMA et al. Ghrelin, an Endogenous Ligand for the Growth Hormone Secretagogue Receptor
CN101128213A (zh) 胰腺β细胞再生的促进剂以及在胰腺β细胞中生产胰岛素的促进剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees